US 12054557
Combination of anti-PD-1 antibodies and bispecific anti-CD20/anti-CD3 antibodies to treat cancer
granted A61KA61K2039/505A61K39/3955
Quick answer
US patent 12054557 (Combination of anti-PD-1 antibodies and bispecific anti-CD20/anti-CD3 antibodies to treat cancer) held by REGENERON PHARMACEUTICALS, INC. expires Mon Aug 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- REGENERON PHARMACEUTICALS, INC.
- Grant date
- Tue Aug 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Aug 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 33
- CPC classes
- A61K, A61K2039/505, A61K39/3955, A61K45/06, A61P